Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by ...

If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...

GLP-1s can result in quick weight loss, but it’s important to understand they are no quick fix or magic bullet. If you don’t develop long-term healthy habits, the weight is likely to return ...

One study he cites in the book showed that 40% of the weight loss in patients on once-a-week injections of semaglutide came from lean body mass. And about a third of that was muscle.

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA approval is expected in 2026.

Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications The study was funded by Eli Lilly, the pharmaceutical company that manufactures ...

METHODOLOGY: GLP-1 RAs are transforming obesity treatment, but high costs and shortages limit patient access. Clinicians have suggested a less frequent dosing to maintain weight loss, but evidence ...

Weight loss drugs might shrink your waistline — but they could also wreck your smile. GLP-1 users have reported a mouthful of problems, including dry mouth, bad breath, gum disease and tooth decay.